Pharmacokinetics of chemotherapy in the older patient

Cancer Control

Volumn 14, Issue 1, 2007, Pages 32-43

  Hurria, Arti ^a   Lichtman, Stuart M ^b  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMETABOLITE; CAPECITABINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOCETAXEL; DOXORUBICIN; ETOPOSIDE; FLUOROURACIL; METHOTREXATE; NAVELBINE; OXALIPLATIN; PACLITAXEL; TAXANE DERIVATIVE; TEMOZOLOMIDE; VINCA ALKALOID;

AGING; AREA UNDER THE CURVE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER RISK; CLINICAL TRIAL; COLORECTAL CANCER; CONTINUOUS INFUSION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SUBSTITUTION; FEBRILE NEUTROPENIA; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; LEUKEMIA; LEUKOCYTE COUNT; MEDICAL LIABILITY; NEUROTOXICITY; NEUTROPENIA; NEUTROPHIL COUNT; POLYPHARMACY; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; THROMBOCYTOPENIA;

EID: 33846553130     PISSN: 10732748     EISSN: 15262359     Source Type: Journal    
DOI: 10.1177/107327480701400105     Document Type: Review

References (97)

1. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80:1273-1283.
2. Yancik R, Ries LA. Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am. 2000;14:17-23.
3. Hutchins LF, Unger JM, Crowley JJ, et al. Underrepresentation of patients 65 years of age or older in cancer- treatment trials. N Engl J Med. 1999;341:2061-2067.
4. Yee KW, Pater JL, Pho L, et al. Enrollment of older patients in cancer treatment trials in Canada: why is age a barrier? J Clin Oncol. 2003;21:1618-1623.
5. Trimble EL, Carter CL, Cain D, et al. Representation of older patients in cancer treatment trials. Cancer. 1994;74(suppl 7):2208-2214.
6. Talarico L, Chen G, Pazdur R. Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration. J Clin Oncol. 2004;22:4626-4631. Erratum in: J Clin Oncol. 2004;22:4811.
7. Kemeny MM, Peterson BL, Kornblith AB, et al. Barriers to clinical trial participation by older women with breast cancer. J Clin Oncol. 2003;21:2268-2275.
8. Newcomb PA, Carbone PP. Cancer treatment and age: patient perspectives. J Natl Cancer Inst. 1993;85:1580-1584.
9. Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer. JAMA. 2005;293:1073-1081.
10. Christman K, Muss HB, Case LD, et al. Chemotherapy of metastatic breast cancer in the elderly. The Piedmont Oncology Association experience. JAMA. 1992;268:57-62.
11. Giovanazzi-Bannon S, Rademaker A, Lai G, et al. Treatment tolerance of elderly cancer patients entered onto phase II clinical trials: an Illinois Cancer Center study. J Clin Oncol. 1994;12:2447-2452.
12. Ibrahim NK, Frye DK, Buzdar AU, et al. Doxorubicin-based chemotherapy in elderly patients with metastatic breast cancer. Tolerance and outcome. Arch Intern Med. 1996;156:882-888.
13. Crivellari D, Bonetti M, Castiglione-Gertsch M, et al. Burdens and benefits of adjuvant cyclophosphamide, methotrexate, and fluorouracil and tamoxifen for elderly patients with breast cancer: the International Breast Cancer Study Group Trial VII. J Clin Oncol. 2000;18:1412-1422.
14. Monfardini S, Aversa SM, Zoli V, et al. Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. Ann Oncol. 2005;16:1352-1358. Epub 2005 Apr 27.
15. Lilenbaum RC, Herndon JE II, List MA, et al. Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer: the cancer and leukemia group B (study 9730). J Clin Oncol. 2005;23:190-196.
16. Sawhney R, Sehl M, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J. 2005;11:449-460.
17. Sehl M, Sawhney R, Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part II. Cancer J. 2005;11:461-473.
18. Duthie ED. Physiology of aging: relevance to symptom perception and treatment tolerance. In: Balducci L, Lyman GH, Ershler WB, et al, eds. Comprehensive Geriatric Oncology. 2nd ed. London; New York: Taylor & Francis; 2004.
19. Yuen GJ. Altered pharmacokinetics in the elderly. Clin Geriatr Med. 1990;6:257-267.
20. Baker SD, Grochow LB. Pharmacology of cancer chemotherapy in the older person. Clin Geriatr Med. 1997;13:169-183.
21. Kastrissios H, Blaschke TF. Medication compliance as a feature in drug development. Annu Rev Pharmacol Toxicol. 1997;37:451-475.
22. Vestal RE. Aging and pharmacology. Cancer. 1997;80:1302-1310.
23. Avorn J, Gurwitz JH. Principles of pharmacology. In Cassel CK, Cohen HJ, Larson EB, et al, eds. Geriatric Medicine. 3rd ed. New York: Springer-Verlag; 1996.
24. Baker SD, van Schaik RH, Rivory LP, et al. Factors affecting cytochrome P-450 3A activity in cancer patients. Clin Cancer Res. 2004;10:8341-8350.
25. Hunt CM, Westerkam WR, Stave GM. Effect of age and gender on the activity of human hepatic CYP3A. Biochem Pharmacol. 1992;44:275-283.
26. Schwartz JB. Race but not age affects erythromycin breath test results in older hypertensive men. J Clin Pharmacol. 2001;41:324-329.
27. Sotaniemi EA, Arranto AJ, Pelkonen O, et al. Age and cytochrome P450-linked drug metabolism in humans: an analysis of 226 subjects with equal histopathologic conditions. Clin Pharmacol Ther. 1997;61:331-339.
28. Evans WE, McLeod HL. Pharmacogenomics - drug disposition, drug targets, and side effects. N Engl J Med. 2003;348:538-549.
29. Flockhart DA, Rae JM. Cytochrome P450 3A pharmacogenetics: the road that needs traveled. Pharmacogenomics J. 2003;3:3-5.
30. Lindeman RD, Tobin J, Shock NW. Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc. 1985;33:278-285.
31. Fehrman-Ekholm I, Skeppholm L. Renal function in the elderly (>70 years old) measured by means of iohexol clearance, serum creatinine, serum urea and estimated clearance. Scand J Urol Nephrol. 2004;38:73-77.
32. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
33. Jelliffe RW. Estimation of creatinine clearance when urine cannot be collected. Lancet. 1971;1:975-976.
34. Rimon E, Kagansky N, Cojocaru L, et al. Can creatinine clearance be accurately predicted by formulae in octogenarian in-patients? QJM. 2004;97:281-287.
35. Burkhardt H, Bojarsky G, Gretz N, et al. Creatinine clearance, Cockcroft-Gault formula and cystatin C: estimators of true glomerular filtration rate in the elderly? Gerontology. 2002;48:140-146.
36. Marx GM, Blake GM, Galani E, et al. Evaluation of the Cockroft-Gault, Jelliffe and Wright formulae in estimating renal function in elderly cancer patients. Ann Oncol. 2004;15:291-295.
37. Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470.
38. Kintzel PE, Dorr RT. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995;21:33-64.
39. Gandhi TK, Weingart SN, Borus J, et al. Adverse drug events in ambulatory care. N Engl J Med. 2003;348:1556-1564.
40. Delafuente JC. Understanding and preventing drug interactions in elderly patients. Crit Rev Oncol Hematol. 2003;48:133-143.
41. Hanlon JT, Pieper CF, Hajjar ER, et al. Incidence and predictors of all and preventable adverse drug reactions in frail elderly persons after hospital stay. J Gerontol A Biol Sci Med Sci. 2006;61:511-515.
42. Zhan C, Sangl J, Bierman AS, et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA. 2001;286:2823-2829.
43. Lichtman SM, Hollis D, Miller AA, et al. Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762). J Clin Oncol. 2006;24:1846-1851.
44. Fidias P, Supko JG, Martins R, et al. A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer. Clin Cancer Res. 2001;7:3942-3949.
45. Smorenburg CH, ten Tije AJ, Verweij J, et al. Altered clearance of unbound paclitaxel in elderly patients with metastatic breast cancer. Eur J Cancer. 2003;39:196-202.
46. Bruno R, Vivier N, Veyrat-Follet C, et al. Population pharmacokinetics and pharmacokinetic-pharmacodynamic relationships for docetaxel. Invest New Drugs. 2001;19:163-169.
47. ten Tije AJ, Verweij J, Carducci MA, et al. Prospective evaluation of the pharmacokinetics and toxicity profile of docetaxel in the elderly. J Clin Oncol. 2005;23:1070-1077.
48. Slaviero KA, Clarke SJ, McLachlan AJ, et al. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol. 2004;57:44-53.
49. Hurria A, Flemming M, Baker SD, et al. Pharmacokinetics and toxicity of weekly docetaxel in the elderly. Clin Cancer Res. In press, 2006.
50. Minami H, Ohe Y, Niho S, et al. Comparison of pharmacokinetics and pharmacodynamics of docetaxel and Cisplatin in elderly and non-elderly patients: why is toxicity increased in elderly patients? J Clin Oncol. 2004;22:2901-2908.
51. Robieux I, Sorio R, Borsatti E, et al. Pharmacokinetics of vinorelbine in patients with liver metastases. Clin Pharmacol Ther. 1996;59:32-40.
52. Sorio R, Robieux I, Galligioni E, et al. Pharmacokinetics and tolerance of vinorelbine in elderly patients with metastatic breast cancer. Eur J Cancer. 1997;33:301-303.
53. Gauvin A, Pinguet F, Culine S, Astre et al. Bayesian estimate of vinorelbine pharmacokinetic parameters in elderly patients with advanced metastatic cancer. Clin Cancer Res. 2000;6:2690-2695.
54. Milano G, Etienne MC, Cassuto-Viguier E, et al. Influence of sex and age on fluorouracil clearance. J Clin Oncol. 1992;10:1171-1175.
55. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer. 1995;75:11-17.
56. Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol. 2002;20:1491-1498.
57. Popescu RA, Norman A, Ross PJ, et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol. 1999;17:2412-2418.
58. Chiara S, Nobile MT, Vincenti M, et al. Advanced colorectal cancer in the elderly: results of consecutive trials with 5-fluorouracil-based chemotherapy. Cancer Chemother Pharmacol. 1998;42:336-340.
59. Sargent DJ, Goldberg RM, Jacobson SD, et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med. 2001;345:1091-1097.
60. Cassidy J, Twelves C, Cameron D, et al. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients. Cancer Chemother Pharmacol. 1999;44:453-460.
61. Poole C, Gardiner J, Twelves C, et al. Effect of renal impairment on the pharmacokinetics and tolerability of capecitabine (Xeloda) in cancer patients. Cancer Chemother Pharmacol. 2002;49:225-234. Epub 2002 Jan 10. Epub 2005 Feb 14.
62. Bajetta E, Procopio G, Celio L, et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol. 2005;23:2155-2161.
63. Camidge R, Reigner B, Cassidy J, et al. Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. J Clin Oncol. 2005;23:4719-4725.
64. Sharma R, Rivory L, Beale P, et al. A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer. Br J Cancer. 2006;94:964-968.
65. Bressolle F, Bologna C, Kinowski JM, et al. Total and free methotrexate pharmacokinetics in elderly patients with rheumatoid arthritis. A comparison with young patients. J Rheumatol. 1997;24:1903-1909.
66. Bressolle F, Bologna C, Kinowski JM, et al. Effects of moderate renal insufficiency on pharmacokinetics of methotrexate in rheumatoid arthritis patients. Ann Rheum Dis. 1998;57:110-113.
67. Gelman RS, Taylor SG IV. Cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in women more than 65 years old with advanced breast cancer: the elimination of age trends in toxicity by using doses based on creatinine clearance. J Clin Oncol. 1984;2:1404-1413.
68. Baker WJ, Royer GL Jr, Weiss RB. Cytarabine and neurologic toxicity. J Clin Oncol. 1991;9:679-693.
69. Rubin EH, Andersen JW, Berg DT, et al. Risk factors for high-dose cytarabine neurotoxicity: an analysis of a Cancer and Leukemia Group B trial in patients with acute myeloid leukemia. J Clin Oncol. 1992;10:948-953.
70. Smith GA, Damon LE, Rugo HS, et al. High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency. J Clin Oncol. 1997;15:833-839.
71. Slevin ML. The clinical pharmacology of etoposide. Cancer. 1991;67(suppl 1):319-329.
72. Toffoli G, Corona G, Sorio R, et al. Population pharmacokinetics and pharmacodynamics of oral etoposide. Br J Clin Pharmacol. 2001;52:511-519.
73. Miller AA, Rosner GL, Ratain MJ, et al. Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a Cancer and Leukemia Group B study (CALGB 9062). Clin Cancer Res. 1997;3:719-725.
74. Ando M, Minami H, Ando Y, et al. Pharmacological analysis of etoposide in elderly patients with lung cancer. Clin Cancer Res. 1999;5:1690-1695.
75. Aita P, Robieux I, Sorio R, et al. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma. Cancer Chemother Pharmacol. 1999;43:287-294.
76. Kawashiro T, Yamashita K, Zhao XJ, et al. A study on the metabolism of etoposide and possible interactions with antitumor or supporting agents by human liver microsomes. J Pharmacol Exp Ther. 1998;286:1294-1300.
77. Dees EC, O'Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest. 2000;18:521-529.
78. Li J, Gwilt PR. The effect of age on the early disposition of doxorubicin. Cancer Chemother Pharmacol. 2003;51:395-402. Epub 2003 Apr 1.
79. Swain SM, Whaley FS, Ewer MS. Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer. 2003;97:2869-2879.
80. Lichtman SM. Physiological aspects of aging. Implications for the treatment of cancer. Drugs Aging. 1995;7:212-225.
81. Daugaard G, Abildgaard U. Cisplatin nephrotoxicity. A review. Cancer Chemother Pharmacol. 1989;25:1-9.
82. Cubillo A, Cornide M, Lopez JL, et al. Renal tolerance to cisplatin in patients 70 years and older. Am J Clin Oncol. 2001;24:192-197.
83. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer: implications of Eastern Cooperative Oncology Group 5592, a randomized trial. J Natl Cancer Inst. 2002;94:173-181.
84. Calvert AH, Egorin MJ. Carboplatin dosing formulae: gender bias and the use of creatinine-based methodologies. Eur J Cancer. 2002;38:11-16.
85. Egorin MJ, Van Echo DA, Olman EA, et al. Prospective validation of a pharmacologically based dosing scheme for the cis-diamminedichloroplatinum(II) analogue diamminecyclobutanedicarboxylatoplatinum. Cancer Res. 1985;45(12 Pt 1):6502-6506.
86. Calvert AH, Newell DR, Gumbrell LA, et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748-1756.
87. Chatelut E, Canal P, Brunner V, et al. Prediction of carboplatin clearance from standard morphological and biological patient characteristics. J Natl Cancer Inst. 1995;87:573-580.
88. Graham M, Lockwood G, Cunningham D, et al. Pharmacokinetics of oxaliplatin in special patient populations. Proc Annu Meet Am Soc Clin Oncol. 1999:728. Abstract.
89. Takimoto CH, Remick SC, Sharma S, et al. Administration of oxaliplatin to patients with renal dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol. 2003;30(4 suppl 15):20-25.
90. Graham MA, Lockwood GF, Greenslade D, et al. Clinical pharmacokinetics of oxaliplatin: a critical review. Clin Cancer Res. 2000;6:1205-1218.
91. Doroshow JH, Synold TW, Gandara D, et al. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol. 2003;30(4 suppl 15):14-19.
92. Goldberg RM, Tabah-Fisch I, Bleiberg H, et al. Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. J Clin Oncol. 2006;24:4085-4091.
93. Beale P, Judson I, Moore S, et al. Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide. Cancer Chemother Pharmacol. 1999;44:389-394.
94. Jen JF, Cutler DL, Pai SM, et al. Population pharmacokinetics of temozolomide in cancer patients. Pharm Res. 2000;17:1284-1289.
95. Borkowski JM, Duerr M, Donehower RC, et al. Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data. Cancer Chemother Pharmacol. 1994;33:493-496.
96. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241-252.
97. Hurria A, Gupta S, Zauderer M, et al. Developing a cancer-specific geriatric assessment: a feasibility study. Cancer. 2005;104:1998-2005.